
Arcellx, Inc. (NASDAQ:ACLX) announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical study of ACLX-001 for patients with Relapsed or Refractory Multiple Myeloma (r/r MM).
The Phase 1 clinical trial is currently evaluating the novel ARC-SparX program in patients with relapsed or refractory multiple myeloma